β-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells

被引:39
作者
Brehm, BR [1 ]
Bertsch, D [1 ]
von Fallois, J [1 ]
Wolf, SC [1 ]
机构
[1] Univ Tubingen, Med Clin 3, D-72076 Tubingen, Germany
关键词
human coronary smooth muscle cells (HCSMC); endothelin-1 (ET-1); beta-blocker; nebivolol; carvedilol;
D O I
10.1097/00005344-200036051-00117
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Endothelin-1 (ET-1) plays an important role in atherogenesis. The aim of the study reported here was to investigate the effects of the third generation beta -blockers nebivolol and carvedilol on ET-1 liberation, preproendothelin-1 production and on proliferation of human coronary cells. Human coronary endothelial (HEC) and smooth muscle cells (HCSMC) were grown with carvedilol or nebivolol (10(-7)-10(-5) mol/l). incubation for 1, 2 or 7 days resulted in an 80% concentration- and time-dependent reduction in HCSMC proliferation. beta -blockers such as propranolol or metoprolol did not influence cell proliferation. Nebivolol (10(-7) mol/l) inhibited accelerated HCSMC proliferation in the presence of growth factors such as transforming growth factor-beta1 or platelet-derived growth factor BB. During incubation with nebivolol or carvedilol ET-1 secretion decreased. For nebivolol this is a result of a reduction in preprolndothelin-1 mRNA levels. beta -blockers of the third generation that reduce the cell proliferation and ET-1 secretion may represent strategies with great promise for antiproliferative therapy of coronary heart disease.
引用
收藏
页码:S401 / S403
页数:3
相关论文
共 12 条
[1]   Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells [J].
Axel, DI ;
Brehm, BR ;
WolburgBuchholz, K ;
Betz, EL ;
Koveker, G ;
Karsch, KR .
JOURNAL OF VASCULAR RESEARCH, 1996, 33 (04) :327-339
[2]   Comparison of circulating endothelin-1 and big endothelin-1 levels in unstable versus stable angina pectoris [J].
Brehm, BR ;
Büttcher, E ;
Beyer, ME ;
Hoffmeister, HM .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 :S90-S93
[3]   GROWTH-CHARACTERISTICS AND CYTOSKELETAL ORGANIZATION OF CULTURED SMOOTH-MUSCLE CELLS FROM HUMAN PRIMARY STENOSING AND RESTENOSING LESIONS [J].
DARTSCH, PC ;
VOISARD, R ;
BAURIEDEL, G ;
HOFLING, B ;
BETZ, E .
ARTERIOSCLEROSIS, 1990, 10 (01) :62-75
[4]   A ROLE FOR ENDOGENOUS ENDOTHELIN-1 IN NEOINTIMAL FORMATION AFTER RAT CAROTID-ARTERY BALLOON ANGIOPLASTY - PROTECTIVE EFFECTS OF THE NOVEL NONPEPTIDE ENDOTHELIN RECEPTOR ANTAGONIST SB-209670 [J].
DOUGLAS, SA ;
LOUDEN, C ;
VICKERYCLARK, LM ;
STORER, BL ;
HART, T ;
FEUERSTEIN, GZ ;
ELLIOTT, JD ;
OHLSTEIN, EH .
CIRCULATION RESEARCH, 1994, 75 (01) :190-197
[5]   A DILEMMA FOR THE 1990S - CHOOSING APPROPRIATE EXPERIMENTAL ANIMAL-MODEL FOR THE PREVENTION OF RESTENOSIS [J].
FERRELL, M ;
FUSTER, V ;
GOLD, HK ;
CHESEBRO, JH .
CIRCULATION, 1992, 85 (04) :1630-1631
[6]   Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis [J].
Grantham, JA ;
Schirger, JA ;
Williamson, EE ;
Heublein, DM ;
Wennberg, PW ;
Kirchengast, M ;
Muenter, K ;
Subkowski, T ;
Burnett, JC .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 :S22-S26
[7]   INVITRO PHARMACOLOGIC PROFILE OF THE NOVEL BETA-ADRENOCEPTOR ANTAGONIST AND VASODILATOR, CARVEDILOL [J].
NICHOLS, AJ ;
SULPIZIO, AC ;
ASHTON, DJ ;
HIEBLE, JP ;
RUFFOLO, RR .
PHARMACOLOGY, 1989, 39 (05) :327-336
[8]   STUDIES ON THE MECHANISM OF ARTERIAL VASODILATION PRODUCED BY THE NOVEL ANTIHYPERTENSIVE AGENT, CARVEDILOL [J].
NICHOLS, AJ ;
GELLAI, M ;
RUFFOLO, RR .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1991, 5 (01) :25-38
[9]   CLINICAL-TRIALS OF RESTENOSIS AFTER CORONARY ANGIOPLASTY [J].
POPMA, JJ ;
CALIFF, RM ;
TOPOL, EJ .
CIRCULATION, 1991, 84 (03) :1426-1436
[10]  
REIDY MA, 1985, LAB INVEST, V53, P513